The US Food and Drug Administration (FDA) has approved bevacizumab-nwgd (Jobevne, Biocon Biologics Ltd), a biosimilar to bevacizumab (Avastin, Genentech), for intravenous use across multiple cancer ...

The FDA has set a goal date of Aug. 27, 2025. If approved, the therapy would be branded as Lytenava and be the first ...

As Avastin needs to be removed from its original vials and introduced into single-use syringes suitable for injection into the eye, Novartis and Roche have long argued that the repackaging ...

Genentech opposes the use of Avastin to treat eye diseases such as macular degeneration, noting that the drug isn't approved by regulators for this purpose. Genentech has a similar drug ...

Caretaker Punjab Minister for Specialized Health Care Dr Javed Akram says so far sixty-eight patients have been affected due to Avastin injection in the province. Addressing the joint press conference ...

Amgen and Allergan's biosimilar of Roche’s cancer drug Avastin is on the cusp of approval in Europe, but a launch could be years away because of patent protection. While the US patent on Avastin ...

Approval was based on data showing no clinically meaningful differences from Avastin in pharmacokinetics, safety, and efficacy. Biocon Biologics Ltd. markets Jobevne in Europe and Canada as Abevmy, ...